160 related articles for article (PubMed ID: 29163701)
1. High levels of DEPDC1B predict shorter biochemical recurrence-free survival of patients with prostate cancer.
Bai S; Chen T; Du T; Chen X; Lai Y; Ma X; Wu W; Lin C; Liu L; Huang H
Oncol Lett; 2017 Dec; 14(6):6801-6808. PubMed ID: 29163701
[TBL] [Abstract][Full Text] [Related]
2. Decreased expression of serine protease inhibitor family G1 (SERPING1) in prostate cancer can help distinguish high-risk prostate cancer and predicts malignant progression.
Peng S; Du T; Wu W; Chen X; Lai Y; Zhu D; Wang Q; Ma X; Lin C; Li Z; Guo Z; Huang H
Urol Oncol; 2018 Aug; 36(8):366.e1-366.e9. PubMed ID: 29903461
[TBL] [Abstract][Full Text] [Related]
3. High Expression of DEPDC1B Predicts Poor Prognosis in Lung Adenocarcinoma.
Li P; Chen X; Zhou S; Xia X; Wang E; Han R; Zeng D; Fei G; Wang R
J Inflamm Res; 2022; 15():4171-4184. PubMed ID: 35912402
[TBL] [Abstract][Full Text] [Related]
4. High expression of ASPM correlates with tumor progression and predicts poor outcome in patients with prostate cancer.
Xie JJ; Zhuo YJ; Zheng Y; Mo RJ; Liu ZZ; Li BW; Cai ZD; Zhu XJ; Liang YX; He HC; Zhong WD
Int Urol Nephrol; 2017 May; 49(5):817-823. PubMed ID: 28213802
[TBL] [Abstract][Full Text] [Related]
5. Enhanced expression of centromere protein F predicts clinical progression and prognosis in patients with prostate cancer.
Zhuo YJ; Xi M; Wan YP; Hua W; Liu YL; Wan S; Zhou YL; Luo HW; Wu SL; Zhong WD; Wu CL
Int J Mol Med; 2015 Apr; 35(4):966-72. PubMed ID: 25647485
[TBL] [Abstract][Full Text] [Related]
6. The metastatic promoter DEPDC1B induces epithelial-mesenchymal transition and promotes prostate cancer cell proliferation via Rac1-PAK1 signaling.
Li Z; Wang Q; Peng S; Yao K; Chen J; Tao Y; Gao Z; Wang F; Li H; Cai W; Lai Y; Li K; Chen X; Huang H
Clin Transl Med; 2020 Oct; 10(6):e191. PubMed ID: 33135357
[TBL] [Abstract][Full Text] [Related]
7. ARRDC3 Inhibits the Progression of Human Prostate Cancer Through ARRDC3-ITGβ4 Pathway.
Zheng Y; Lin ZY; Xie JJ; Jiang FN; Chen CJ; Li JX; Zhou X; Zhong WD
Curr Mol Med; 2017; 17(3):221-229. PubMed ID: 28782483
[TBL] [Abstract][Full Text] [Related]
8. High level of androgen receptor is associated with aggressive clinicopathologic features and decreased biochemical recurrence-free survival in prostate: cancer patients treated with radical prostatectomy.
Li R; Wheeler T; Dai H; Frolov A; Thompson T; Ayala G
Am J Surg Pathol; 2004 Jul; 28(7):928-34. PubMed ID: 15223964
[TBL] [Abstract][Full Text] [Related]
9. Role of DEP domain-containing protein 1B (DEPDC1B) in epithelial ovarian cancer.
Wu Y; Yin H; Zhang X; Shen R; Zhu X; Jia M
J Cancer; 2023; 14(5):784-792. PubMed ID: 37056386
[TBL] [Abstract][Full Text] [Related]
10. Clinical significance of NUCB2 mRNA expression in prostate cancer.
Zhang H; Qi C; Li L; Luo F; Xu Y
J Exp Clin Cancer Res; 2013 Aug; 32(1):56. PubMed ID: 23958433
[TBL] [Abstract][Full Text] [Related]
11. Prognostic implications of tissue and serum levels of microRNA-128 in human prostate cancer.
Sun X; Yang Z; Zhang Y; He J; Wang F; Su P; Han J; Song Z; Fei Y
Int J Clin Exp Pathol; 2015; 8(7):8394-401. PubMed ID: 26339409
[TBL] [Abstract][Full Text] [Related]
12. Aberrantly high DEPDC1B expression leads to poor prognosis in patients with lower-grade gliomas.
Liu ZD; Liang WJ; Cheng XB; Qian RJ; Gao YZ
Eur Rev Med Pharmacol Sci; 2022 Nov; 26(21):7813-7826. PubMed ID: 36394729
[TBL] [Abstract][Full Text] [Related]
13. Overexpression levels of cripto-1 predict poor prognosis in patients with prostate cancer following radical prostatectomy.
Liu Y; Wang J; Yang T; Liu R; Xu Y
Oncol Lett; 2019 Sep; 18(3):2584-2591. PubMed ID: 31452743
[TBL] [Abstract][Full Text] [Related]
14. Increased Paxillin expression in prostate cancer is associated with advanced pathological features, lymph node metastases and biochemical recurrence.
Zheng QS; Chen SH; Wu YP; Chen HJ; Chen H; Wei Y; Li XD; Huang JB; Xue XY; Xu N
J Cancer; 2018; 9(6):959-967. PubMed ID: 29581775
[No Abstract] [Full Text] [Related]
15. Upregulation of Holliday junction recognition protein predicts poor prognosis and biochemical recurrence in patients with prostate cancer.
Chen YF; Liang YX; Yang JA; Yuan DZ; Li J; Zheng SS; Wan YP; Wang B; Han ZD; Zhong WD
Oncol Lett; 2019 Dec; 18(6):6697-6703. PubMed ID: 31814851
[TBL] [Abstract][Full Text] [Related]
16. Association of microRNA-21 expression with clinicopathological characteristics and the risk of progression in advanced prostate cancer patients receiving androgen deprivation therapy.
Guan Y; Wu Y; Liu Y; Ni J; Nong S
Prostate; 2016 Aug; 76(11):986-93. PubMed ID: 27040772
[TBL] [Abstract][Full Text] [Related]
17. Prognostic role of XTP1/DEPDC1B and SDP35/DEPDC1A in high grade soft-tissue sarcomas.
Pollino S; Benassi MS; Pazzaglia L; Conti A; Bertani N; Righi A; Piccinni-Leopardi M; Picci P; Perris R
Histol Histopathol; 2018 Jun; 33(6):597-608. PubMed ID: 29297565
[TBL] [Abstract][Full Text] [Related]
18. L-dopa decarboxylase (DDC) gene expression is related to outcome in patients with prostate cancer.
Koutalellis G; Stravodimos K; Avgeris M; Mavridis K; Scorilas A; Lazaris A; Constantinides C
BJU Int; 2012 Sep; 110(6 Pt B):E267-73. PubMed ID: 22571720
[TBL] [Abstract][Full Text] [Related]
19. DEPDC1B promotes migration and invasion in pancreatic ductal adenocarcinoma by activating the Akt/GSK3β/Snail pathway.
Liu X; Li T; Huang X; Wu W; Li J; Wei L; Qian Y; Xu H; Wang Q; Wang L
Oncol Lett; 2020 Nov; 20(5):146. PubMed ID: 32934714
[TBL] [Abstract][Full Text] [Related]
20. Increasing of FKBP9 can predict poor prognosis in patients with prostate cancer.
Jiang FN; Dai LJ; Yang SB; Wu YD; Liang YX; Yin XL; Zou CY; Zhong WD
Pathol Res Pract; 2020 Jan; 216(1):152732. PubMed ID: 31780055
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
